Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM
Another week of big moves in the resource sector was had, but that is what it is for most weeks.
AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Update on UK Availability of AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown
Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU
